Endothelial Progenitor Cells (EPC) with Colony Forming Capacity Are Derived from the Monocytic-Macrophage Lineage.

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 4228-4228
Author(s):  
Natalia Lopez-Holgado ◽  
Mercedes Alberca Graduate ◽  
Eva M. Villaron ◽  
Julia Almeida ◽  
Alejandro Martin ◽  
...  

Abstract The existence of circulating endothelial progenitor cells (EPC) in adult humans is under intensive investigation due to its potential clinical application. In the present study we have attempted to identify the EPC with colony forming capacity and compare their characteristics with those of the monocytic-macrophage lineage. 42 healthy donors were analysed (7 Bone Marrow, 20 steady-state Peripheral Blood (PB), 4 apheresis products from mobilised PB and 9 buffy-coat products). Median age was 38 years and M/F ratio was 19/23. EPC were obtained by culturing MNC in IMDM with VEGF and beta-FGF. At day 7 the colonies were counted and flow cytometry and immunohistochemistry studies were carried out. Sequential studies were performed on days +21, +28 and +35 of culture with vascular growth factors. Monocytic cells were obtained by adhesion to plastic surface or CD14+ cell selection using magnetic microbeads (Miltenyi, Biotech). Then, monocytic cells were cultured using the same conditions as EPC until day +21 or alternatively with VEGF, beta-FGF and IGF. Von Willebrand gene expression was analysed by RT-PCR and the formation of vascular structures was analyzed by Matrigel assays on both cell sources, EPC and monocytic cells. The mean number of EPC colonies at day 7 was significantly higher in BM (813±695) than in steady-state PB (21.2±2.5), while mobilized PB displayed intermediate values (272±274). By contrast, using the same medium as EPC, monocytic cells did not form colonies at day 7, but cord-like structures could be seen in 7 out 9 cases. However, when the cells were cultured by adding IGF to the medium, a greater number of colonies could be observed. By immunohistochemistry colonies were positive for CD45, CD31 and lysozyme but negative for vWf. Flow cytometry analysis showed that colonies were positive for CD4, CD13, CD14, CD31, CD33, CD45, lysozyme and VE-cadherin, weak positive for CD15 and CD105, and did not express CD16, CD34, CD133 or KDR. This phenotypic profile remained unchanged at all time-points analysed. The immunophenotype of cultured monocytes at day +21 was identical to that of pre-cultured monocytes and both were similar to those obtained in EPC, even for the “specific” markers lysozyme and VE-cadherin. PCR analysis showed small amounts of vWF transcripts in EPC as well as in monocytes but the expression increased after culture with VEGF. Finally, when matrigel assays were carried out, we observed that monocytes formed cord- and tubular-like structures to a higher extent than EPC. Our results in both cell subtypes suggest that the so “called” EPC belongs to the monocytic cell lineage and both populations express some “specific” endothelial antigens such as CD31 or VE-cadherin, as well as monocytic markers such as lysozyme.

2019 ◽  
Vol 142 (2) ◽  
pp. 113-119
Author(s):  
Martin Řádek ◽  
Eva Babuňková ◽  
Martin Špaček ◽  
Tomáš Kvasnička ◽  
Jan Kvasnička

Background/Aims: Endothelial progenitor cells (EPCs) and circulating endothelial cells (CECs) have been described as markers of endothelial damage and dysfunction in several diseases, including deep venous thrombosis. Their role in patients with known thrombophilia has not yet been evaluated. Both EPCs and CECs represent extremely rare cell populations. Therefore, it is essential to use standardized methods for their identification and quantification. Methods: In this study, we used multicolor flow cytometry to analyze the number of EPCs and CECs in patients with thrombophilia with or without a history of thrombosis. Patients with hematological malignancies after high-dose chemotherapy and patients with acute myocardial infarction were used as positive controls. Results: EPC and CEC immunophenotypes were determined as CD45dim/–CD34+CD146+CD133+ and CD45dim/–CD34+CD146+CD133–, respectively. Increased levels of endothelial cells were observed in positive control groups. No significant changes in the number of EPCs or CECs were detected in patients with thrombophilia compared to healthy controls. Conclusion: Our optimized multicolor flow cytometry method allows unambiguous identification and quantification of endothelial cells in the peripheral blood. Our results support previous studies showing that elevated levels of CECs could serve as an indicator of endothelial injury or dysfunction. Normal levels of CECs or EPCs were found in patients with thrombophilia.


2016 ◽  
Vol 63 (3) ◽  
Author(s):  
Jolanta Kiewisz ◽  
Monika M. Kaczmarek ◽  
Anna Pawlowska ◽  
Zbigniew Kmiec ◽  
Tomasz Stompor

Endothelial progenitor cells (EPCs) represent a small population of blood cells (5-40 cells/mm3), with an ability to differentiate into endothelial cells that form the lining of the blood vessels and contribute to postnatal angiogenesis. Abundant evidence shows that recruitment of EPCs from the bone marrow, the monocyte/macrophage lineage and the organs facilitate the endothelial regeneration and repair. Changes in the number of EPCs were observed in both, chronic kidney and cardiovascular diseases. Thus, these cells were tested for usage in diagnosis and therapy. In this paper, we review the current knowledge on the EPC biology and contribution of these cells to the kidney and cardiovascular diseases.


Blood ◽  
2004 ◽  
Vol 103 (4) ◽  
pp. 1373-1375 ◽  
Author(s):  
Ying Yu ◽  
Alan F. Flint ◽  
John B. Mulliken ◽  
June K. Wu ◽  
Joyce Bischoff

Abstract Infantile hemangioma is an endothelial tumor that grows rapidly after birth but slowly regresses during early childhood. Initial proliferation of hemangioma is characterized by clonal expansion of endothelial cells (ECs) and neovascularization. Here, we demonstrated mRNA encoding CD133-2, an important marker for endothelial progenitor cells (EPCs), predominantly in proliferating but not involuting or involuted hemangioma. Progenitor cells coexpressing CD133 and CD34 were detected by flow cytometry in 11 of 12 proliferating hemangioma specimens from children 3 to 24 months of age. Furthermore, in 4 proliferating hemangiomas, we showed that 0.14% to 1.6% of CD45– nucleated cells were EPCs that coexpressed CD133 and the EC marker KDR. This finding is consistent with the presence of KDR+ immature ECs in proliferating hemangioma. Our results suggest that EPCs contribute to the early growth of hemangioma. To our knowledge, this is the first study to show direct evidence of EPCs in a human vascular tumor.


2012 ◽  
Vol 84 (3) ◽  
pp. 384-386 ◽  
Author(s):  
Vicky Y. Hoymans ◽  
Amaryllis H. Van Craenenbroeck ◽  
Luc Bruyndonckx ◽  
Sabrina H. van Ierssel ◽  
Christiaan J. Vrints ◽  
...  

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 298-298 ◽  
Author(s):  
Martin Korbling ◽  
James M. Reuben ◽  
Hui Gao ◽  
Bang-Ning Lee ◽  
Sergio A. Giralt ◽  
...  

Abstract Endothelial progenitor cells (EPCs) have been identified as part of hematopoietic tissue-derived progenitor cells that are mobilized into the peripheral blood (PB) as a result of tissue injury. It therefore seems likely that circulating EPCs have therapeutic potential by aiding in the neovascularization of ischemic tissue. It was the purpose of this study to provide clinical data on the availability of circulating EPCs at steady-state and after rhG-CSF mobilization, and their collection by leukapheresis. Eight healthy donors underwent rhG-CSF (10 μg/kg) treatment over 4 days. Continuous-flow leukapheresis (COBE Spectra, Version 4.7) was performed on the fourth day of rhG-CSF treatment. Blood samples were drawn before starting rhG-CSF treatment, before apheresis, and from the apheresis collection bag. The total cell numbers collected per apheresis were based on processing a median of 17 L [10.7–20.1] blood volume or approximately three times the donor’s total blood volume. Blood and apheresis samples were analyzed by flow cytometry for EPC surface markers CD34, CD133, VEGFR-2, and by forming EPC colonies (CFU-EPC). The Wilcoxon matched-pairs signed-ranks test was used to compare the distributions at various sampling points. All CD133 subsets were CD14 negative to exclude differentiated monocytes or macrophages. The median steady-state PB concentrations of circulating CD34+CD133+VEGFR-2+ cells was 0.9/μl [0–3], or 1.7/μl [0.9–4] for CD34+133−VEGFR-2+ EPCs. After 4 days of rhG-CSF mobilization treatment the PB CD34+CD133+VEGFR-2+ subset concentration increased by a median of 8-fold [p 0.01], and the CD34+133−VEGFR-2+ subset concentration by a median of 10-fold [p 0.01] over baseline. The median PB concentration of circulating CFU-EPCs increased by 10-fold [p 0.02]. The median absolute number of CD34+CD133+VEGFR-2+ and CD34+CD133-VEGFR-2+ cells collected by leukapheresis per kg of body weight was 0.845 x 106 [0.12–2.55] and 1.54 x 106 [0.06–2.4], respectively. A small population of CD133+34− VEGFR-2+ cells was identified in steady state and mobilized PB, and in the apheresis collect (0.11 x 106/kg [0–0.26]). CD34− progenitor cells expressing CD133 are believed to represent a primitive progenitor cell population containing SCID-repopulating cells. VEGFR-2 coexpression of those immature cells may define a circulating cell population that contributes to vasculogenesis. Our data suggest that clonogenic circulating EPCs can be mobilized by rhG-CSF and collected by continuous-flow leukapheresis generating large numbers of EPCs, specifically in the range of 60 x 106 EPCs per leukapheresis procedure for a 70 kg individual. Circulating EPCs represent a novel blood cell component that can be clinically used in large quantities, either unmanipulated or EPC-selected, for therapeutic vasculogenesis.


Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 2984-2984
Author(s):  
Sadeaqua S Scott ◽  
Marc J Braunstein ◽  
Christopher Lange ◽  
Christopher Roman ◽  
Eric LP Smith ◽  
...  

Abstract Abstract 2984 Background: Multiple myeloma (MM), a neoplasm of committed B-lymphocytes within the bone marrow (BM), is the second most common hematologic malignancy in the U.S. Despite prolonged median survival with anti-myeloma strategies aimed at the tumor and its BM microenvironment, MM remains invariably fatal. Endothelial progenitor cells (EPCs) are CD133+/KDR+ cells that originate in the BM and play a key role in supporting tumor growth and MM progression. Using X-chromosome inactivation and RT-PCR analyses, we previously found EPCs from MM patients to be clonally restricted and to display clonotypic IG heavy-chain gene rearrangements identical to the same patients' tumor cells (Braunstein et al., 2006). Based on the shared genetic identity that we and others have demonstrated between tumor cells and EPCs in MM patients, the present study explored the hypothesis that, similar to hemangioblasts, which are CD133-expressing precursors to adult hematopoietic and endothelial cells, EPCs may be a source of vascular and MM progenitor cells. Since hemangioblasts are known to exist predominately in the quiescent phases of the cell cycle, in this study we also examined the cell cycle status of CD133-expressing BM cells from MM patients in order to gain insight into their hemangioblastic traits. Methods: BM aspirates were acquired from MM patients under IRB approval. EPCs (>98% vWF/CD133/KDR+ and CD38-) from BM aspirates of MM patients were outgrown on laminin-coated flasks as previously described. The spleen colony assay was used to determine the stem cell capacity within BM-derived EPCs by i.v. injection into NOD/SCID mice. The spleens and BM of mice were harvested 2–4 weeks later. Cells were analyzed by immunofluorescence (IF) and flow cytometry. Hoechst 33342 (Hst) and Pyronin Y (PY) were used to measure the cell cycle status of CD133+ cells using FACS analysis. Results: Two to four weeks following i.v. injection of MM EPCs, human cell surface marker expression detected by flow cytometry within mouse BM and spleen cells shifted from CD133+/CD45-lo, a progenitor cell phenotype, to CD133−/CD45-hi, a more differentiated phenotype, suggesting the ability of MM EPCs to differentiate in vivo. Cell cycle analysis of the CD133+ population in BM cells of MM patients showed that these cells were predominantly non-cycling. On average, 60.5% of CD133+ cells were found to be in the G0/G1 phase of the cell cycle, as indicated by low levels of IF staining with Hst and PY. Conclusions: CD133+ cells are strong candidates as precursors to MM tumor and vascular progenitor cells. As quiescent cells are non-dividing, they often escape cytotoxic effects of chemotherapy, resulting in relapse, and therefore, identification of these cells is critical. Ongoing studies include the engraftment of CD133+ cells in the subcutaneous NOD/SCID gamma xenotransplant model and their growth in response to anti-myeloma strategies; results of these studies will be discussed. Disclosures: No relevant conflicts of interest to declare.


Sign in / Sign up

Export Citation Format

Share Document